Enzyme Replacement Therapy Market Size, Share & Growth | 2030
Enzyme Replacement Therapy Market Size, Share & Growth | 2030
Segments - Global Enzyme Replacement Therapy Market by Route of Administration (Oral, Parenteral), Therapeutic Conditions (Gaucher Disease, Fabry Disease, Pompe Disease, SCID, MPS, Other Disease), and Regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2020 – 2027
Upcoming
| Report ID :HC-92
| 4.4 Rating
| 74 Reviews
| 140 Pages
| Format :
Report Description
Enzyme Replacement Therapy Market Outlook
The global enzyme replacement therapy market was valued at USD 9,955.4 Million in 2019 and is projected to reach USD 16,362.2 Million by 2027, expanding at a CAGR of 6.8% during the forecast period. Enzyme replacement therapy (ERT) is one of the important medical treatments prescribed to provide the enzymes that are deficient in the body. It replenishes the deficient enzymes in the patient’s body either through the intravenous (IV) or oral routes of administration. The IV route is widely accepted by people, these drugs are easily and rapidly absorbed in the body.
Enzyme deficiencies in body can hamper the metabolism of glycogen, which results in the accumulation of glycogen in tissue, bones, and cardiac muscle. Deficiency of enzyme can result in a life-changing or life-threatening conditions. Enzyme replacement therapy is used for the treatment of ailments such as Gaucher Disease, Fabry Disease, Pompe Disease, SCID, and MPS Disease. These diseases are genetic disorders and can be transferred from parents to their children, if both the parents suffer from the ailment. These diseases cannot be cured completely; however, they can be controlled by replacing the enzymes that are lacking in the human body.
In terms of route of administration, the enzyme replacement therapy market has been bifurcated into injectable agents and oral agents. Solid dosage form in enzyme replacement therapy are given through the oral route of administration to fulfil the enzyme deficiency in the body. Enzyme replacement therapy through oral route include the tablets dosage form containing the enzyme.
These enzymes are administered to fulfil the enzyme deficiency in the patient’s body. Zavesca is the oral drug developed by Actelion Pharmaceuticals Ltd indicated for the treatment of Gaucher’s disease. The oral route is more convenient than the parenteral route, as these drugs are easy to store and transport. Moreover, tablets are premeasured doses, which eliminates the need for measuring the medicine.
These factors are fuelling the growth of oral route of administration segment. Parenteral and oral medicines are available in market and are used for the treatment of ERT to treat diseases such as Gaucher’s diseases and Fabry diseases. Key players in the market are focused on developing drugs for both these routes of administration.
Enzyme Replacement Therapy Market Dynamics
Increased Prevalence of Chronic Diseases
Increasing prevalence of chronic diseases and life-threatening lysosomal storage diseases such as Gaucher, Pompe, Fabry, and SCID is expected to boost the global enzyme replacement therapy market. Rising awareness among people about the availability of ERT is encouraging and driving the market growth.
Technological Advancement Leading to Adoption of Technologies
Growing technological advancements have led to the adoption of technologies, which has increased the focus of manufacturers on drug development processes and the development of innovative therapies. This, in turn, is expected to propel the market growth during the forecast period. High absorption rate and rapid drug delivery through parenteral route of administration is driving the demand for parenteral dosage. Increasing financial support for rare diseases (including lysosomal storage diseases) by government and non-governmental organizations (NGOs) is projected to boost the market.
Segmental Outlook
On the basis of route of administration, the enzyme replacement therapy market has been divided into oral and parenteral. Parenteral and oral medicines are available in the market and are used for the treatment of ERT to treat diseases such as Gaucher’s diseases and Fabry diseases. Key players in the market are focused on developing drugs for these routes of administration.
Solid dosage form in enzyme replacement therapy are given through the oral route of administration to fulfil the enzyme deficiency in the body. Enzyme replacement therapy through oral route which includes the tablets dosage form containing the enzyme. These enzymes are administered to fulfil the enzyme deficiency in the patient’s body.
Zavesca is the oral drug developed by Actelion Pharmaceuticals Ltd indicated for the treatment of Gaucher’s disease. The oral route is more convenient than the parenteral route, as these drugs are easy to store and transport. Moreover, tablets are premeasured doses, which eliminates the need for measuring the medicine. These factors are fuelling the growth of oral route of administration segment.
Parenteral route of administration in enzyme replacement therapy are given through the intravenous (IV) route, which is a fast route of delivery and shows rapid absorption as compared to oral route of administration. High availability of a large variety of parenteral enzyme replacement therapy is driving the demand of parenteral ERT, thus making it highly preferred treatment type for EMT. Cerezyme (imiglucerase), VPRIV (velaglucerase alfa), and ELELYSO (taliglucerase alfa) are major drugs used for injections and providing treatment for Gaucher’s disease as injectable agents.
Based on therapeutic conditions, the enzyme replacement therapy market has been segmented into Gaucher’s diseases, Fabry disease, Pompe diseases, Severe Combined Immunodeficiency (SCID), Mucopolysaccharidosis (MPS) disease, and others. ERT is prescribed to treat several diseases, especially to people who have a particular enzyme deficiency. Increasing prevalence of such diseases is expected to drive the enzyme replacement therapy market.
Regional Outlook
In terms of regions, the market has been fragmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is a promising region for the market. It constituted a 31.1% share of the market in 2019. Asia Pacific held significant market share of 25.7% in 2019. Availability of technological advancements and awareness among people drive the market in North America, followed by Europe. A majority of manufacturers are focused on developing the enzyme replacement therapy for treating a number of diseases.
This is expected to boost the market during the forecast period. The market in Asia Pacific is expected to grow at a significant pace due to increasing population and growing prevalence of chronic and rare diseases.
Segments
Types
- Oral
- Parenteral
Therapeutic Condition
- Gaucher Disease
- Fabry Disease
- Pompe Disease
- MPS Disease
- Other Diseases
Regions
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Europe
- Germany
- France
- Italy
- U.K.
- Spain
- Russia
- Rest of the Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- South East Asia (SEA)
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- Saudi Arabia
- South Africa
- UAE
- Rest of MEA
Key Players
- Sanofi
- Takeda Pharmaceutical Company Limited
- BioMarin
- AbbVie Inc.
- Alexion Pharmaceuticals, Inc
- Horizon Therapeutics plc
- RECORDATI S.p.A.
- PROTALIX BIOTHERAPEUTICS, INC.
- Allergan
- Pfizer Inc.
- Leadiant Biosciences, Ltd.
Competitive Landscape
-
Key players in the market include Sanofi, Takeda Pharmaceutical Company Limited, BioMarin, AbbVie Inc, Alexion Pharmaceuticals, Inc., Horizon Therapeutics plc, RECORDATI S.p.A., PROTALIX BIOTHERAPEUTICS, INC., Allergan, Pfizer Inc., and Leadiant Biosciences, Ltd. These companies are considered as key manufacturers of enzyme replacement based on their revenue, research & development (R&D) activities, regional presence, and supply chain management system.
- The players are adopting key strategies such as acquisition, product launch, and geographical expansion where potential opportunity for the enzyme replacement is added in the company’s capacity.
- In March 8, 2018, Sanofi acquired Bioverativ Inc. The acquisition has helped the company strengthen its pharmaceutical segments. The company’s net sales at a constant exchange rate rose by 2.5%, reflecting the acquisition of Bioverativ Inc.’s rare blood disorder products.
- In 2018, January 8, 2019, Takeda Pharmaceutical Company Limited acquired SHIRE PLC. The acquisition helped the company with a substantial rise in their product offerings and their geographical presence.
Key Benefits for Industry Participants & Stakeholders
- In-depth Analysis of the Global Enzyme Replacement Market
- Historical, Current and Projected Market Size in terms of Value
- Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
- Industry Drivers, Restraints and Opportunities Covered in the Study
- Recent Industry Trends and Developments
- Competitive Landscape & Strategies of Key Players
- Neutral Perspective on Global Enzyme Replacement Market Performance
Frequently Asked Questions
Additional company profiles can be provided on request.
Yes, the report covers therapeutic condition specific information.
According to this Growth Market Reports report, the market from enzyme replacement is likely to register a CAGR of 6.8% during forecast period 2020-2027, with an anticipated valuation of USD 16,362.2 million by the end of the 2027.
In addition to market size (in USD Million), company Market Share (in % for base year 2019), other data such as COVID-19 Impact on the enzyme replacement market, Macro-economic factors are available in the final report.
The increasing plantation activities for fulfilling the accelerated demand for enzyme replacement is to drive the market growth.
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
The market is expected to witness slight decline between 2019 and 2020 owing to the impact of COVID-19 pandemic on the enzyme replacement market.
The base year considered for the global enzyme replacement market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017 & 2018 are the historic years and the forecast is provided from 2020 to 2027.
Hospitals, clinics are the key end-user that are driving the enzyme replacement market.
Major Manufactures include, Sanofi, Takeda Pharmaceutical Company Limited, BioMarin, AbbVie Inc, Alexion Pharmaceuticals, Inc., Horizon Therapeutics plc, RECORDATI S.p.A., PROTALIX BIOTHERAPEUTICS, INC., Allergan, Pfizer Inc., and Leadiant Biosciences, Ltd.
Table Of Content
Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Enzyme Replacement Therapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Enzyme Replacement Therapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Enzyme Replacement Therapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Enzyme Replacement Therapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Enzyme Replacement Therapy Market Size & Forecast, 2017-2027
4.5.1 Enzyme Replacement Therapy Market Size and Y-o-Y Growth
4.5.2 Enzyme Replacement Therapy Market Absolute $ Opportunity
Chapter 5 Global Enzyme Replacement Therapy Market Analysis and Forecast By Route of Administration
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Route of Administration
5.1.2 Basis Point Share (BPS) Analysis By Route of Administration
5.1.3 Absolute $ Opportunity Assessment By Route of Administration
5.2 Enzyme Replacement Therapy Market Size Forecast By Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.3 Market Attractiveness Analysis By Route of Administration
Chapter 6 Global Enzyme Replacement Therapy Market Analysis and Forecast By Therapeutic Condition
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Therapeutic Condition
6.1.2 Basis Point Share (BPS) Analysis By Therapeutic Condition
6.1.3 Absolute $ Opportunity Assessment By Therapeutic Condition
6.2 Enzyme Replacement Therapy Market Size Forecast By Therapeutic Condition
6.2.1 Gaucher Disease
6.2.2 Fabry Disease
6.2.3 Pompe Disease
6.2.4 SCID
6.2.5 MPS Disease
6.2.6 Other Diseases
6.3 Market Attractiveness Analysis By Therapeutic Condition
Chapter 7 Global Enzyme Replacement Therapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Enzyme Replacement Therapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Enzyme Replacement Therapy Analysis and Forecast
9.1 Introduction
9.2 North America Enzyme Replacement Therapy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Enzyme Replacement Therapy Market Size Forecast By Route of Administration
9.6.1 Oral
9.6.2 Parenteral
9.7 Basis Point Share (BPS) Analysis By Route of Administration
9.8 Absolute $ Opportunity Assessment By Route of Administration
9.9 Market Attractiveness Analysis By Route of Administration
9.10 North America Enzyme Replacement Therapy Market Size Forecast By Therapeutic Condition
9.10.1 Gaucher Disease
9.10.2 Fabry Disease
9.10.3 Pompe Disease
9.10.4 SCID
9.10.5 MPS Disease
9.10.6 Other Diseases
9.11 Basis Point Share (BPS) Analysis By Therapeutic Condition
9.12 Absolute $ Opportunity Assessment By Therapeutic Condition
9.13 Market Attractiveness Analysis By Therapeutic Condition
Chapter 10 Europe Enzyme Replacement Therapy Analysis and Forecast
10.1 Introduction
10.2 Europe Enzyme Replacement Therapy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Enzyme Replacement Therapy Market Size Forecast By Route of Administration
10.6.1 Oral
10.6.2 Parenteral
10.7 Basis Point Share (BPS) Analysis By Route of Administration
10.8 Absolute $ Opportunity Assessment By Route of Administration
10.9 Market Attractiveness Analysis By Route of Administration
10.10 Europe Enzyme Replacement Therapy Market Size Forecast By Therapeutic Condition
10.10.1 Gaucher Disease
10.10.2 Fabry Disease
10.10.3 Pompe Disease
10.10.4 SCID
10.10.5 MPS Disease
10.10.6 Other Diseases
10.11 Basis Point Share (BPS) Analysis By Therapeutic Condition
10.12 Absolute $ Opportunity Assessment By Therapeutic Condition
10.13 Market Attractiveness Analysis By Therapeutic Condition
Chapter 11 Asia Pacific Enzyme Replacement Therapy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Enzyme Replacement Therapy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Enzyme Replacement Therapy Market Size Forecast By Route of Administration
11.6.1 Oral
11.6.2 Parenteral
11.7 Basis Point Share (BPS) Analysis By Route of Administration
11.8 Absolute $ Opportunity Assessment By Route of Administration
11.9 Market Attractiveness Analysis By Route of Administration
11.10 Asia Pacific Enzyme Replacement Therapy Market Size Forecast By Therapeutic Condition
11.10.1 Gaucher Disease
11.10.2 Fabry Disease
11.10.3 Pompe Disease
11.10.4 SCID
11.10.5 MPS Disease
11.10.6 Other Diseases
11.11 Basis Point Share (BPS) Analysis By Therapeutic Condition
11.12 Absolute $ Opportunity Assessment By Therapeutic Condition
11.13 Market Attractiveness Analysis By Therapeutic Condition
Chapter 12 Latin America Enzyme Replacement Therapy Analysis and Forecast
12.1 Introduction
12.2 Latin America Enzyme Replacement Therapy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Enzyme Replacement Therapy Market Size Forecast By Route of Administration
12.6.1 Oral
12.6.2 Parenteral
12.7 Basis Point Share (BPS) Analysis By Route of Administration
12.8 Absolute $ Opportunity Assessment By Route of Administration
12.9 Market Attractiveness Analysis By Route of Administration
12.10 Latin America Enzyme Replacement Therapy Market Size Forecast By Therapeutic Condition
12.10.1 Gaucher Disease
12.10.2 Fabry Disease
12.10.3 Pompe Disease
12.10.4 SCID
12.10.5 MPS Disease
12.10.6 Other Diseases
12.11 Basis Point Share (BPS) Analysis By Therapeutic Condition
12.12 Absolute $ Opportunity Assessment By Therapeutic Condition
12.13 Market Attractiveness Analysis By Therapeutic Condition
Chapter 13 Middle East & Africa (MEA) Enzyme Replacement Therapy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Enzyme Replacement Therapy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Enzyme Replacement Therapy Market Size Forecast By Route of Administration
13.6.1 Oral
13.6.2 Parenteral
13.7 Basis Point Share (BPS) Analysis By Route of Administration
13.8 Absolute $ Opportunity Assessment By Route of Administration
13.9 Market Attractiveness Analysis By Route of Administration
13.10 Middle East & Africa (MEA) Enzyme Replacement Therapy Market Size Forecast By Therapeutic Condition
13.10.1 Gaucher Disease
13.10.2 Fabry Disease
13.10.3 Pompe Disease
13.10.4 SCID
13.10.5 MPS Disease
13.10.6 Other Diseases
13.11 Basis Point Share (BPS) Analysis By Therapeutic Condition
13.12 Absolute $ Opportunity Assessment By Therapeutic Condition
13.13 Market Attractiveness Analysis By Therapeutic Condition
Chapter 14 Competition Landscape
14.1 Enzyme Replacement Therapy Market: Competitive Dashboard
14.2 Global Enzyme Replacement Therapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie inc.
14.3.2 Alexion Pharmaceuticals,Inc.
14.3.3 Allergan
14.3.4 BioMarin
14.3.5 Horizon Therapeutics plc.
14.3.6 Leadiant Biosciences, Ltd.
14.3.7 Pfizer Inc.
14.3.8 PROTALIX BIOTHERAPEUTICS, INC.
14.3.9 RECORDATI S.p.A
14.3.10 Sanofi
14.3.11 Takeda Pharmaceutical Limited
Methodology
Related Reports
Some other reports from this category!
Our Clients
